Melinda L. Telli, M.D.

Medical oncologist

Breast specialist

Breast Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Center for Lymphatic and Venous Disorders

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-6459
Learn More About the Clinic Getting Here Make An Appointment

Women's Cancer Center

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University School of Medicine (2008) CA

Medical Education: George Washington University Medical School (2002) DC

Board Certification: Medical Oncology, American Board of Internal Medicine (2008)

B.A., University of Pennsylvania, Biology, with Distinction (1996)

M.D., George Washington University, Medicine, with Distinction (2002)

Residency, Stanford University, Internal Medicine (2005)

Fellowship, Stanford University, Medical Oncology (2008)

Board Certification: Internal Medicine, American Board of Internal Medicine (2005)

Board Certification, Medical Oncology, ABIM (2008)

Residency: Stanford University Medical Center (2005) CA

Honors & Awards

Career Catalyst Research Award, Susan G. Komen for the Cure (2012)

New Investigator Award, Stanford Cancer Institute (2011)

Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012, 2013)

Young Investigator Award, American Society of Clinical Oncology (2009)

Fellowship Award, Susan G. Komen for the Cure (2008)

Merit Award, American Society of Clinical Oncology (2008)

Administrative Appointments

Breast Cancer Panel, National Comprehensive Cancer Network, 2014

Medical Oncology SEP Committee, American Board of Internal Medicine, 2014

Breast Cancer Maintenance of Certification Working Group, American Society of Clinical Oncology, 2013

Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology, 2010

Program Committee, ASCO Breast Cancer Symposium, 2010

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Hospital & Clinics patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
Telli, M. L. (2013). Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(29).

Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Witteles, R. M., & Telli, M. (2012). Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?. JOURNAL OF CLINICAL ONCOLOGY, 30(16), 1916-1918.

PARP inhibitors in cancer: moving beyond BRCA
Telli, M. L. (2011). PARP inhibitors in cancer: moving beyond BRCA. LANCET ONCOLOGY, 12(9), 827-828.

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. Hm., McClure, L. A., & Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471-478.

Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?
Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(20), 1644-1650.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613-1618.

Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007). Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. JOURNAL OF CLINICAL ONCOLOGY, 25(23), 3525-3533.

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., & Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast cancer research : BCR, 16(2), R36.

(18)F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients.
Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., & Gambhir, S. S. (2014). (18)F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. Radiology, 140028.

Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli, M. (2014). Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 34, e37-42.

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., & Jeffrey, S. S. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC cancer, 14(1), 456.

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059-1066.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., & Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, electronic publication ahead of print, October 30.

Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science, 2013, 62-?.

Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., & Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939-942.

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., & Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125-1130.

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, Aa. H., Zhang, H., Coram, M. A., Reddy, A., & Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).

Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.
Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., & Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and science of sleep, 4, 151-162.

Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
Witteles, R. M., Fowler, M. B., & Telli, M. L. (2011). Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?. HEART FAILURE CLINICS, 7(3), 333-?.

Trastuzumab-Related Cardiac Dysfunction
Telli, M. L., & Witteles, R. M. (2011). Trastuzumab-Related Cardiac Dysfunction. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(2), 243-249.

PARP inhibitors in breast cancer.
Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical advances in hematology & oncology : H&O, 8(9), 629-635.

Novel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16-E22.

Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., & Clarke, C. A. (2010). Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. JOURNAL OF CLINICAL ONCOLOGY, 28(10), E155-E157.

Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605-613.

First-Line Chemotherapy for Metastatic Breast Cancer
Telli, M. L., & Carlson, R. W. (2009). First-Line Chemotherapy for Metastatic Breast Cancer. CLINICAL BREAST CANCER, 9, S66-S72.

Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
Telli, M. L., Horst, K. C., Guardino, A. E., Dirbas, F. M., & Carlson, R. W. (2007). Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Journal of the National Comprehensive Cancer Network , 5(3), 324-330.

Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells
Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., & Williamson, J. R. (1999). Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. BIOCHEMICAL PHARMACOLOGY, 57(4), 425-432.